Unknown

Dataset Information

0

PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.


ABSTRACT: Krukenberg tumor (KT) is an uncommon ovarian metastatic signet-ring cell adenocarcinoma that mostly metastasizes from gastrointestinal carcinoma. Optimal treatment options for KTs are limited. Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have shown remarkable activity in clinical trials for metastatic tumors. Here, we evaluated PD-L1 expression and T cell infiltration in KTs and their corresponding primary tumors. Positive tumor PD-L1 expression was detected in 9 (25.7%) KTs from gastric carcinomas (GCs) and in 20 (66.7%) KTs from colorectal carcinomas (CRCs). Patient survival was assessed according to the PD-L1 status and CD8+ T cell density. Positive tumor PD-L1 expression in KTs from GCs was associated with poor prognosis. In contrast, positive tumor PD-L1 expression in KTs from CRCs was associated with an improved prognosis. We analyzed copy number variations of the PD-L1 gene in KTs. PD-L1 expression was higher in cases with copy number gains. The T cell densities within KTs and their corresponding primary tumors were compared. The densities of CD8+ T cells correlated significantly between the primary tumors and KTs from the same case. Taken together, the research further highlighted targets for immune-based therapy in KTs from GCs and CRCs.

SUBMITTER: Tai H 

PROVIDER: S-EPMC5964418 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.

Tai Haiyan H   Yang Qin Q   Wu Zhiyong Z   Sun Su'an S   Cao Rui R   Xi Yanfeng Y   Zhao Ran R   Zhang Mengyu M   Zhang Zhigang Z   Xu Congjian C  

Journal of immunology research 20180508


Krukenberg tumor (KT) is an uncommon ovarian metastatic signet-ring cell adenocarcinoma that mostly metastasizes from gastrointestinal carcinoma. Optimal treatment options for KTs are limited. Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have shown remarkable activity in clinical trials for metastatic tumors. Here, we evaluated PD-L1 expression and T cell infiltration in KTs and their corresponding primary tumors. Positive tumor PD-L1 expression was detected in 9 (25.7%  ...[more]

Similar Datasets

| S-EPMC5609984 | biostudies-literature
| S-EPMC8604387 | biostudies-literature
| S-EPMC6797961 | biostudies-literature
| S-EPMC9714418 | biostudies-literature
| S-EPMC5494943 | biostudies-other
| S-EPMC5560454 | biostudies-other
| S-EPMC5510474 | biostudies-literature
| S-EPMC5685163 | biostudies-literature
| S-EPMC7082005 | biostudies-literature
| S-EPMC7057441 | biostudies-literature